N
TRAX

Nuveen’s First Tracks Biotherapeutics TRAX Stock Holding History

Nuveen’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$998K Buy
+49,608
New +$927K ﹤0.01% 2943

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen's TRAX Position: Q2 2026 in Review

Nuveen opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 49,608 shares worth $998K. The stake represents ﹤0.01% of the portfolio and ranks #2943 among its holdings.

80 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Nuveen held 49,608 shares of First Tracks Biotherapeutics worth $998K as of Q2 2026.
  • First Tracks Biotherapeutics was a new Nuveen position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2943 holding.
  • 80 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.